Niraparib for maintenance treatment of advanced ovarian, fallopian tube and peritoneal cancer after response to first-line platinum-based chemotherapy- guidance (TA673)

NICE recommends niraparib for use within the Cancer Drugs Fund as an option for maintenance treatment in this population provided conditions in the managed access agreement for niraparib are followed.

National Institute for Health and Care Excellence